Crossmark

Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study

Crossref DOI link: https://doi.org/10.1007/s00277-025-06684-5

Published Online: 2025-10-08

Published Print: 2025-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Xianghui

Xia, Xin

Bian, Lingyun

Shen, Zaihong

Zhou, Kun

Wan, Liping

Song, Xianmin

Tong, Yin
License Information

Text and Data Mining valid from 2025-09-01

Version of Record valid from 2025-10-08
More Information

Article History

Received: 2 September 2024

Accepted: 1 October 2025

First Online: 8 October 2025

Declarations

:

: This study was approved by the Ethics Review Committee of Shanghai General Hospital (approval reference number: 02.DY11.06.22.06, approval date: 2017.01). Title of the approved project is “Antiviral drugs combined with mesenchymal stem cells for the treatment of cytomegalovirus pneumonia after allogeneic hematopoietic stem cell transplantation”. Written informed consent was obtained for all patients before they were enrolled in the study.

: Consent for publication was obtained from the participants.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below